Hostname: page-component-76fb5796d-5g6vh Total loading time: 0 Render date: 2024-04-28T05:37:56.147Z Has data issue: false hasContentIssue false
  • English
  • Français

Identifying Vulnerability Markers in Prodromal Patients: A Step in the Right Direction for Schizophrenia Prevention

Published online by Cambridge University Press:  07 November 2014

Lucy Knowles  and
Tonmoy Sharma
Get access Rights & Permissions [Opens in a new window]

Abstract

Research has shown that many of the long-term deficits that are observable in schizophrenia populations are present prior to the emergence of psychotic symptoms. Recent research suggests schizophrenia has a “prodromal” period, whereby significant changes from premorbid functioning can be observed. Accurate classification of this period could have far-reaching implications for schizophrenia prevention. This article aims to provide an indepth evaluation of the perceived benefits of vulnerability marker research in this unique phase. It is hoped that identification of such markers may improve the predictive potency of prodromal criteria, and perhaps pave the way for future screening and primary prevention strategies.

Type
Review Article
Information
CNS Spectrums , Volume 9 , Issue 8 , August 2004 , pp. 595 - 602
Copyright
Copyright © Cambridge University Press 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Jablensky, A, Sartorius, N, Enberg, G et al. , Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl. 1992;20:722–730.CrossRefGoogle ScholarPubMed
2. Murray, CJL, Lopez, AD. The Global Burden of Disease. Boston, Mass: Harvard University Press; 1996Google ScholarPubMed
3. Hegarty, JD, Baldessarini, RJ, Tohen, M et al. , One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994:151:1409–1416.Google ScholarPubMed
4. Sullivan, HS. The onset of schizophrenia. 1927. Am J Psychiatry. 1994;151:135–139.Google Scholar
5. Cameron, DE. Early Schizophrenia. Am J Psycluatry. 1938;95:567–578.CrossRefGoogle Scholar
6. Meares, A. The diagnosis of prepsychotic schizophrenia. Lancet. 1959;55–59.Google Scholar
7. Crow, TJ, MacMillan, JF, Johnson, AL et al. , A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry. 1986;148:120–127.CrossRefGoogle ScholarPubMed
8. Rahiner, CJ. Wegner, JT. Kane, JM. Outcome study of first-episode psychosis. I: Relapse rates after 1 year. Am J Psychiatry. 1986;143:1155–1158.Google Scholar
9. Falloon, IRH. Early Intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry. 1992;55:4–15.CrossRefGoogle ScholarPubMed
10. Loebel, AD, Lieherman, JA, Alvir, JM et al. , Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992;149:1183–1188.Google ScholarPubMed
11. McGlashan, THEarly detection and intervention in schizophrenia. Schizopkr Bull. 1996;22:327–346.CrossRefGoogle ScholarPubMed
12. McGorry, P. Preventive strategies in early psychosis: verging on reality. Br J Psychiatry. 1998;172(suppl 33):1–2.CrossRefGoogle ScholarPubMed
13. Haas, GL, Garratt, LS, Sweeney, JA. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. J Psychiatr Res. 1998;13(suppl 3):31–34.Google Scholar
14. Larsen, TK, Johannessen, JO, Opjordsmoen, S. First episode schizophrenia with long duration of untreated psychosis. Br J Psychiatry. 1998;172(suppl 33):40–45.CrossRefGoogle ScholarPubMed
15. Loebel, AD, Lieberman, JA, Alvir, JM et al. , Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992;149:1183–1188.Google ScholarPubMed
16. Lieberman, JA, Koreen, AR. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizopkr Bull. 1993;2:371–428.CrossRefGoogle Scholar
17. Wyatt, RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17:325–351CrossRefGoogle ScholarPubMed
18. Wyatt, RJ, Green, MF, Tuma, AH. Long-term morbidity associated with delayed treatment of first admission schizophrenia patients: a re-analysis of the Camarillo State Hospital data. Psychol Med. 1997;27:261–268.CrossRefGoogle ScholarPubMed
19. Edwards, J, McGorry, PD. Implementing Early Intervention in Psychosis: A Guide to Establishing Early Psychosis Services. London, England: Martin Dunitz; 2002.CrossRefGoogle Scholar
20. Herz, M, Melville, C. Relapse in schizophrenia. Am J Psychiatry. 1980;137:801–805.Google ScholarPubMed
21. Birchwood, M, Smith, J, Macmillan, F et al. , Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers. Psychol Med. 1989;19:649–656.CrossRefGoogle ScholarPubMed
22. Jorgensen, P. Early signs of psychotic relapse in schizophrenia. Br J Psychiatry. 1998;172:327–330.CrossRefGoogle ScholarPubMed
23. Beiser, M, Erickson, D, Fleming, JA et al. , Establishing the onset of psychotic illness. Am J Psychiatry. 1993;150:1349–1354.Google ScholarPubMed
24. Duzyurek, S, Weiner, JM. Early recognition in schizophrenia: the prodromal stages. Journal of Practical Psychology and Behavioural Health. 1999;5:187–196.Google Scholar
25. McGorry, PD, McFarlane, C, Patton, GC et al. , The prevalence if prodromal features of schizophrenia in adolescence: a preliminary survey. Acta Psychiatr Scand. 1995;92:241–249.CrossRefGoogle ScholarPubMed
26. Johannessen, J, Larsen, T, McGlashan, T. Duration of untreated psychosis: an important target for intervention in schizophrenia? Nord J Psychiatry. 1999:53:275–283.Google Scholar
27. Comblatt, B, Lencz, T, Obuchowski, M. The schizophrenia prodrome: treatment and high-risk perspectives. Schizophr Res. 2002;54:177–186.CrossRefGoogle Scholar
28. McGlashan, TH, Miller, TJ, Woods, SW. Pre-onset detection and intervention research in schizophrenia in psychoses. Schizophr Bull. 2001;27:563–570.CrossRefGoogle ScholarPubMed
29. Yung, AR, McGorry, PD. The prodromal phase of first episode psychosis: past and current conceptualisations. Schizopkr Bull. 1996;22:353–370.CrossRefGoogle Scholar
30. McGlashan, TH. Early detection and intervention of schizophrenia: rationale and research. Br J Psychiatry. 1998;172(suppl 33):3–6.CrossRefGoogle ScholarPubMed
31. Pantelis, C, Velakoulis, D, McGorry, PD et al. , Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet. 2003;361:281–288.CrossRefGoogle ScholarPubMed
32. Wolkin, A, Rusinek, H. A neuropathology ofpsychosis? Lancet. 2003;361:270–271.CrossRefGoogle Scholar
33. Birchwood, M, Macmillan, F. Early intervention in schizophrenia. Aust N Z J Psychiatry. 1993;27:374–378.CrossRefGoogle ScholarPubMed
34. Fava, GA, Kellner, R. Prodromal symptoms in affective disorders. Am J Psychiatry. 1991:148:823–830.Google ScholarPubMed
35. Diagnostic and Statistical Manual for Mental Disorders. 3rd ed-rev. Washington, DC: American Psychiatric Association; 1987.Google Scholar
36. Jackson, HJ, McGorry, PD, Dudgeon, P. Prodromal symptoms of schizophrenia in firstepisode psychosis: prevalence and specificity. Compr Psychiatry. 1995;36:241–250.CrossRefGoogle ScholarPubMed
37. Häfner, H, Lffler, W, Maurer, K et al. , Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr. Scand. 1999;100:105–118.CrossRefGoogle ScholarPubMed
38. Diagnostic and Statistical Manual for Mental Disorders. 4th ed Washington, DC: American Psychiatric Association; 1994.Google Scholar
39. Häfner, H, An Der Heiden, W. The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. Eur Arch Psychiatry Clin Neurosci. 1999;249(suppl 4):14–26.CrossRefGoogle ScholarPubMed
40. Bell, RQ. Multiple-risk cohorts and segmenting risk as solutions to the problem of false positives in risk for the major psychoses. Psychiatry. 1992;55:370–381.CrossRefGoogle Scholar
41. Yung, AR, Phillips, LJ, McGorry, PD et al. , Prediction ofpsychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl. 1998;172;14–20.CrossRefGoogle ScholarPubMed
42. Davidson, M, Reichenberg, A, Rabinowitz, J et al. , Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry. 1999;156:1328–1335.CrossRefGoogle ScholarPubMed
43. Jones, P, Done, D. From birth to onset: a developmental perspective of schizophrenia in two national birth cohorts. In: Keshavan, M, Murray, R eds. Newodevelopmental Models of Psychopathology. Cambridge, England: Cambridge University Press; 1997:119–136.Google Scholar
44. Klosterkotter, J, Gross, G, Huber, G et al. , Are self-perceivable neuropsychological deficits in patients with neuroses or personality disorder indicative of later schizophrenia [German]? Nervenartzt. 1997;68:196–204.Google ScholarPubMed
45. Tsuang, MT, Faraone, SV, Bingham, S et al. , Department of Veterans Affairs Cooperative Studies Program genetic linkage study of schizophrenia: ascertainment methods and sample description. Am J Med Genet. 2000;96:342–347.3.0.CO;2-J>CrossRefGoogle ScholarPubMed
46. Phillips, LJ, Yung, AR, McGorry, PD. Identification of young people at risk of psychosis: validation of personal assessment and crisis evaluation clinic intake criteria. Aust N Z J Psychiatry. 2000;34(suppl):S164–S169.CrossRefGoogle ScholarPubMed
47. Jolley, AG, Hirsch, SR, Morrison, E et al. , Trial of brief intermittent neuroleptic prophalaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ. 1990;301:837–842.CrossRefGoogle Scholar
48. Rosen, JL, Woods, SW, Miller, TJ et al. , Prospective observations of emerging psychosis. J Nen Mew Dis. 2002;190;133–141.Google ScholarPubMed
49. Phillips, L, Yung, AR, Hearn, N et al. , Preventative mental health care: accessing the target population. Aust N Z J Psychiatry. 1999;33:912–917.CrossRefGoogle ScholarPubMed
50. Yung, AR, Phillips, LJ, Yuen, HP et al. , Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophr Res. 2003;60:21–32.CrossRefGoogle ScholarPubMed
51. Cook, RJ, Sackett, DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452–454.CrossRefGoogle Scholar
52. Eaton, WW, Harrison, G. Prevention priorities. Curr Opin Psychiatry. 1996:9:141–143.CrossRefGoogle Scholar
53. Copolov, D, Crook, J. Biological markers and schizophrenia. Aust N Z J Psychiatry. 2000;34(suppl):S108–S112.CrossRefGoogle ScholarPubMed
54. Mednick, SA, Parnas, J, Schulsinger, F. The Copenhagen High Risk Project 1962–1986. Schizophr Bull. 1987:13:485–496.CrossRefGoogle Scholar
55. Weintraub, S. Risk Factors in schizophrenia: the Stony Brook high-risk project. Schizophr Bull. 1987:13:439–450.CrossRefGoogle ScholarPubMed
56. Asarnow, JR. Children at risk for schizophrenia: converging lines of evidence. Schizophr Bull. 1988;14:613–631.CrossRefGoogle ScholarPubMed
57. Erlenmeyer-Kimling, L, Cornblatt, B, Rock, D et al. , The New York High Risk Project: Anhedonia, attentional deviance and psychopathology. Schizophr Bull. 1993;19:141–153.CrossRefGoogle ScholarPubMed
58. Gottesman, II. Schizophrma Genesis: The Origin of Madness. New York, NY: Freeman; 1991.Google Scholar
59. Cornblatt, B, Obuchowski, M. Update of high-risk research: 1987–1997. Int Rev Psychiatry. 1997:9:437–447.Google Scholar
60. Johnstone, EC, Cosway, R, Lawrie, SM. Distinguishing characteristics of subjects with good and poor early outcome in the Edinburgh High-Risk Study. Br J Psychiatry Suppl. 2002;43:S26–S29.CrossRefGoogle ScholarPubMed
61. Kendler, KS. Familial aggregation of schizophrenia and schizophrenia spectrum. Arch Gen Psychiatry. 1988:45:323–327.CrossRefGoogle ScholarPubMed
62. McGullfin, P, Farmer, AE, Gottesman, M et al. , Twin concordance for operationally defined schizophrenia. Arch Gen Psychiatry. 1984:49:541–545.CrossRefGoogle Scholar
63. Cornblatt, B. The New York High Risk Project to the Hillside Recognition and Prevention (RAP) Program. Am J Med Genet. 2002;114:956–966.CrossRefGoogle Scholar
64. Mrazek, PJ, Haggerty, RJ. Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research. Washington, DC: National Academy Press; 1994.Google Scholar
65. Thompson, KT, McGorry, PD, Phillips, LJ et al. , Prediction and Intervention in the pre-psychotic phase. Journal of Advances in Schizophrenia and Brain Research. 2001;3:43–47.Google Scholar
66. Yung, AR, McGorry, PD. Is pre-psychotic intervention realistic in schizophrenia and related disorders? Aust N Z J of Psychiatry. 1997:31:799–805.CrossRefGoogle ScholarPubMed
67. Velakoulis, D, Phillips, L, McGorry, PD et al. , Larger left hippocampal volume predicts transition to psychosis in an ultra high risk group. Schizophr Res. 2000;41:117.CrossRefGoogle Scholar
68. Yung, AR, Phillips, LJ, McGorry, PD et al. , Can we predict the onset of first episode psychosis in a high risk group? Int Clin Psychopharmacol. 1998;13:S23–S30.CrossRefGoogle Scholar
69. Phillips, LJ, Yung, AR, McGorry, PD. Identification of young people at risk of psychosis: validation of personal assessment and crisis evaluation clinic intake criteria. Aust N Z J Psychiatry. 2000;34(suppl):S164–S169.CrossRefGoogle ScholarPubMed
70. Corcoran, C, Gallitano, A, Leitman, D et al. , The neurobiology of the stress cascade and its potential relevance for schizophrenia. Journal of Psychiatry Practice. 2001;7:3–14.CrossRefGoogle ScholarPubMed
71. McGorry, PD. The nature of schizophrenia: signposts to prevention. Aust N Z J Psychiatry. 2000;34(suppl):S14–S21.CrossRefGoogle ScholarPubMed
72. Brewer, W, Francey, S, Yung, A et al. , Cognitive and olfactory deficit: course from high risk to first episode research. Schizophr Res. 1998:29:1–2.CrossRefGoogle Scholar
73. Hambrecht, M, Lammertink, M, Klosterkotter, J et al. , Subjective and objective neuropsychological abnormalities in a psychosis prodrome clinic. Br J Psychiatry. 2002;181(Suppl 43):S30–S37.CrossRefGoogle Scholar
74. McGlashan, TH, Zipursky, RB, Perkins, D et al. , The PRIME North America randomised double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromal symptomatic for psychosis I. Study rationale and design. Schizophr Res. 2003;61;7–18.CrossRefGoogle ScholarPubMed
75. Jung, MJ, Schmauss, C. Decreased c-fos responses to D2-receptor agonist stimulation in mice deficient for D3 receptors. J Biol Chem. 1999;274:29406–29412.CrossRefGoogle Scholar
76. Castner, SA, Williams, GV, Goldman-Rakic, PS. Reversal of antipsychoticinduced working memory deficits by short-term dopamine Dl receptor stimulation. Science. 2000;287:2020–2022.CrossRefGoogle Scholar
77. Kraemer, HC, Stice, E, Kazdin, A et al. , How do risk factors work together? Mediators, moderators, and independent, overlapping and proxy risk factors. Am J Psychiatry. 2001:158:848–856.CrossRefGoogle ScholarPubMed
78. Bovet, P, Gamma, F. Vulnerability to schizophrenia: relevance of patients' subjective experience for empirical and clinical work. Am J Med Genet. 2002;114:923–926.CrossRefGoogle ScholarPubMed